California-based biotech BioAge Labs will have its initial public offering of stock. The company is developing Azelaprag, a ...

BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the ...

Discover the revival of the biotech sector, with IPOs resurging and promising weight loss drug potential, despite facing ...

Weight-loss drug developer BioAge Labs (BIOA) on Wednesday announced the pricing of its upsized initial public offering of 11 ...

(Reuters) -BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United ...

BioAge Labs is eyeing around $180 million in initial proceeds from an IPO and a private placement, funds the ...

BioAge Labs (BIOA) shares rallied nearly 30% Thursday after the obesity drug developer made its market debut through an upsized $198M initial public offering. Read more here.

BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its ...

The offering, which was upsized twice, will support development of a drug the company believes can boost the effects of ...

BioAge Labs, Inc BIOA IPO will take place September, 26 on the NASDAQ exchange under the ticker BIOA. The company is offering ...

BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of ...

Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial ...